Inicio
Resultado de la búsqueda
4 búsqueda de la palabra clave 'review'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Título : Biomarkers of pituitary neoplasms Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : Anticancer Research Idioma : Inglés (eng) Palabras clave : Angiogenesis apoptosis p53 p27 cox-2 folliculostellate cells galectin-3 hif-1alpha inflammation and tumor matrix metalloproteinases (MMPS) microarray microenvironment microvessel density (MVD) pituitary stem cells proliferative marker (ki-67) pituitary tumor-transforming gene (PTTG) topoisomerase-2-alpha tumor heterogeneity VEGF review Resumen : In a wide spectrum of tumors, cell proliferation, vascularity, apoptosis, cell adhesion, and cell-cycle progression may indicate tumor progression. In this review article, the literature regarding apoptotic markers and p53, as well as cyclooxygenase-2, galectin-3, and pituitary tumor transforming factor, proliferative markers, angiogenesis, including vascular endothelial growth factor and its receptor, pituitary tumor-transforming gene, microarrays, stem cells, and microenvironment and tumor heterogeneity are presented. Only a particular group of selected biomarkers show promise in differentiating pituitary tumors which will behave in an aggressive manner. Therefore, the most common and promising biomarkers and terms were analyzed, proposing the need for uniform design and application of methods and standardized criteria for the interpretation of results. The new spectrum of biomarkers may shed light upon the pathogenetic mechanisms and also may serve as standardized diagnostic tool for daily pathologic practice. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V. Syro, Bernd W. Scheithauer, and Kalman Kovacs Referencia : Anticancer Res. 2012; 32:(11)4639-54. En línea : http://ar.iiarjournals.org/content/32/11/4639.abstract Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3635 Biomarkers of pituitary neoplasms [documento electrónico] / Luis Vicente Syro Moreno, . - 2012.
Obra : Anticancer Research
Idioma : Inglés (eng)
Palabras clave : Angiogenesis apoptosis p53 p27 cox-2 folliculostellate cells galectin-3 hif-1alpha inflammation and tumor matrix metalloproteinases (MMPS) microarray microenvironment microvessel density (MVD) pituitary stem cells proliferative marker (ki-67) pituitary tumor-transforming gene (PTTG) topoisomerase-2-alpha tumor heterogeneity VEGF review Resumen : In a wide spectrum of tumors, cell proliferation, vascularity, apoptosis, cell adhesion, and cell-cycle progression may indicate tumor progression. In this review article, the literature regarding apoptotic markers and p53, as well as cyclooxygenase-2, galectin-3, and pituitary tumor transforming factor, proliferative markers, angiogenesis, including vascular endothelial growth factor and its receptor, pituitary tumor-transforming gene, microarrays, stem cells, and microenvironment and tumor heterogeneity are presented. Only a particular group of selected biomarkers show promise in differentiating pituitary tumors which will behave in an aggressive manner. Therefore, the most common and promising biomarkers and terms were analyzed, proposing the need for uniform design and application of methods and standardized criteria for the interpretation of results. The new spectrum of biomarkers may shed light upon the pathogenetic mechanisms and also may serve as standardized diagnostic tool for daily pathologic practice. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V. Syro, Bernd W. Scheithauer, and Kalman Kovacs Referencia : Anticancer Res. 2012; 32:(11)4639-54. En línea : http://ar.iiarjournals.org/content/32/11/4639.abstract Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3635 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000206 AC-2012-046 Archivo digital Producción Científica Artículos científicos Disponible
Título : Pituitary tumors in patients with MEN1 syndrome Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : Clinics (Sao Paulo) Idioma : Inglés (eng) Palabras clave : Pituitary neoplasms multiple endocrine neoplasia type 1 review genetics Resumen : We briefly review the characteristics of pituitary tumors associated with multiple endocrine neoplasia type 1. Multiple endocrine neoplasia type 1 is an autosomal-dominant disorder most commonly characterized by tumors of the pituitary, parathyroid, endocrine-gastrointestinal tract, and pancreas. A MEDLINE search for all available publications regarding multiple endocrine neoplasia type 1 and pituitary adenomas was undertaken. The prevalence of pituitary tumors in multiple endocrine neoplasia type 1 may vary from 10% to 60% depending on the studied series, and such tumors may occur as the first clinical manifestation of multiple endocrine neoplasia type 1 in 25% of sporadic and 10% of familial cases. Patients were younger and the time between initial and subsequent multiple endocrine neoplasia type 1 endocrine lesions was significantly longer when pituitary disease was the initial manifestation of multiple endocrine neoplasia type 1. Tumors were larger and more invasive and clinical manifestations related to the size of the pituitary adenoma were significantly more frequent in patients with multiple endocrine neoplasia type 1 than in subjects with non-multiple endocrine neoplasia type 1. Normalization of pituitary hypersecretion was much less frequent in patients with multiple endocrine neoplasia type 1 than in subjects with non-multiple endocrine neoplasia type 1. Pituitary tumors in patients with multiple endocrine neoplasia type 1 syndrome tend to be larger, invasive and more symptomatic, and they tend to occur in younger patients when they are the initial presentation of multiple endocrine neoplasia type 1. Mención de responsabilidad : Luis V Syro, Bernd W Scheithauer, Kalman Kovacs, Rodrigo A Toledo, Francisco J Londoño, Leon D Ortiz, Fabio Rotondo, Eva Horvath, Humberto Uribe Referencia : Clinics (Sao Paulo). 2012;67 Suppl 1:43-8. DOI (Digital Object Identifier) : 10.6061/clinics/2012(Sup01)09 PMID : 22584705 En línea : https://www.revistas.usp.br/clinics/article/view/19720 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3610 Pituitary tumors in patients with MEN1 syndrome [documento electrónico] / Luis Vicente Syro Moreno, . - 2012.
Obra : Clinics (Sao Paulo)
Idioma : Inglés (eng)
Palabras clave : Pituitary neoplasms multiple endocrine neoplasia type 1 review genetics Resumen : We briefly review the characteristics of pituitary tumors associated with multiple endocrine neoplasia type 1. Multiple endocrine neoplasia type 1 is an autosomal-dominant disorder most commonly characterized by tumors of the pituitary, parathyroid, endocrine-gastrointestinal tract, and pancreas. A MEDLINE search for all available publications regarding multiple endocrine neoplasia type 1 and pituitary adenomas was undertaken. The prevalence of pituitary tumors in multiple endocrine neoplasia type 1 may vary from 10% to 60% depending on the studied series, and such tumors may occur as the first clinical manifestation of multiple endocrine neoplasia type 1 in 25% of sporadic and 10% of familial cases. Patients were younger and the time between initial and subsequent multiple endocrine neoplasia type 1 endocrine lesions was significantly longer when pituitary disease was the initial manifestation of multiple endocrine neoplasia type 1. Tumors were larger and more invasive and clinical manifestations related to the size of the pituitary adenoma were significantly more frequent in patients with multiple endocrine neoplasia type 1 than in subjects with non-multiple endocrine neoplasia type 1. Normalization of pituitary hypersecretion was much less frequent in patients with multiple endocrine neoplasia type 1 than in subjects with non-multiple endocrine neoplasia type 1. Pituitary tumors in patients with multiple endocrine neoplasia type 1 syndrome tend to be larger, invasive and more symptomatic, and they tend to occur in younger patients when they are the initial presentation of multiple endocrine neoplasia type 1. Mención de responsabilidad : Luis V Syro, Bernd W Scheithauer, Kalman Kovacs, Rodrigo A Toledo, Francisco J Londoño, Leon D Ortiz, Fabio Rotondo, Eva Horvath, Humberto Uribe Referencia : Clinics (Sao Paulo). 2012;67 Suppl 1:43-8. DOI (Digital Object Identifier) : 10.6061/clinics/2012(Sup01)09 PMID : 22584705 En línea : https://www.revistas.usp.br/clinics/article/view/19720 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3610 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000180 AC-2012-020 Archivo digital Producción Científica Artículos científicos Disponible
Título : Temozolomide in aggressive pituitary adenomas and carcinomas Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : Clinics (Sao Paulo) Idioma : Inglés (eng) Palabras clave : Pituitary adenoma pituitary carcinoma MGMT temozolomide review Resumen : Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6 -methylguanine- DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the available publications regarding the use of temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophysial tumors that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus, temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates that there is an inverse correlation between levels of O6 -methylguanine-DNA methyltransferase immunoexpression and therapeutic response. Alternatively, high-level O6 -methylguanine-DNA methyltransferase immunoexpression correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms. Mención de responsabilidad : Leon D Ortiz, Luis V Syro, Bernd W Scheithauer, Fabio Rotondo, Humberto Uribe, Camilo E Fadul, Eva Horvath, Kalman Kovacs Referencia : Clinics. 2012;67(S1):119-23. DOI (Digital Object Identifier) : 10.6061/clinics/2012(Sup01)20 PMID : 22584716 En línea : https://www.revistas.usp.br/clinics/article/view/19731 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3606 Temozolomide in aggressive pituitary adenomas and carcinomas [documento electrónico] / Luis Vicente Syro Moreno, . - 2012.
Obra : Clinics (Sao Paulo)
Idioma : Inglés (eng)
Palabras clave : Pituitary adenoma pituitary carcinoma MGMT temozolomide review Resumen : Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6 -methylguanine- DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the available publications regarding the use of temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophysial tumors that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus, temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates that there is an inverse correlation between levels of O6 -methylguanine-DNA methyltransferase immunoexpression and therapeutic response. Alternatively, high-level O6 -methylguanine-DNA methyltransferase immunoexpression correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms. Mención de responsabilidad : Leon D Ortiz, Luis V Syro, Bernd W Scheithauer, Fabio Rotondo, Humberto Uribe, Camilo E Fadul, Eva Horvath, Kalman Kovacs Referencia : Clinics. 2012;67(S1):119-23. DOI (Digital Object Identifier) : 10.6061/clinics/2012(Sup01)20 PMID : 22584716 En línea : https://www.revistas.usp.br/clinics/article/view/19731 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3606 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000176 AC-2012-016 Archivo digital Producción Científica Artículos científicos Disponible Endoglin (CD105) : a review of its role in angiogenesis and tumor diagnosis, progression and therapy / Luis Vicente Syro Moreno
Título : Endoglin (CD105) : a review of its role in angiogenesis and tumor diagnosis, progression and therapy Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2011 Títulos uniformes : Anticancer Research Idioma : Inglés (eng) Palabras clave : Angiogenesis cancer CD105 endoglin tumor review Resumen : Endoglin (CD105) is an accessory receptor for transforming growth factor beta (TGF-β) and its expression is up-regulated in actively proliferating endothelial cells. Endoglin has been suggested as an appropriate marker for tumor-related angiogenesis and neovascularization. Several studies demonstrate the potential of endoglin in tumor diagnosis, prognosis, and therapy. This review details the structure and function of endoglin, and investigates the role of endoglin in angiogenesis and tumor diagnosis, prognosis, and therapy. Mención de responsabilidad : Farshad Nassiri, Michael D Cusimano, Bernd W Scheithauer, Fabio Rotondo, Alessandra Fazio, George M Yousef, Luis V Syro, Kalman Kovacs, Ricardo V Lloyd Referencia : Anticancer Res. 2011 Jun;31(6):2283-90. PMID : 21737653 En línea : http://ar.iiarjournals.org/content/31/6/2283.full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3555 Endoglin (CD105) : a review of its role in angiogenesis and tumor diagnosis, progression and therapy [documento electrónico] / Luis Vicente Syro Moreno, . - 2011.
Obra : Anticancer Research
Idioma : Inglés (eng)
Palabras clave : Angiogenesis cancer CD105 endoglin tumor review Resumen : Endoglin (CD105) is an accessory receptor for transforming growth factor beta (TGF-β) and its expression is up-regulated in actively proliferating endothelial cells. Endoglin has been suggested as an appropriate marker for tumor-related angiogenesis and neovascularization. Several studies demonstrate the potential of endoglin in tumor diagnosis, prognosis, and therapy. This review details the structure and function of endoglin, and investigates the role of endoglin in angiogenesis and tumor diagnosis, prognosis, and therapy. Mención de responsabilidad : Farshad Nassiri, Michael D Cusimano, Bernd W Scheithauer, Fabio Rotondo, Alessandra Fazio, George M Yousef, Luis V Syro, Kalman Kovacs, Ricardo V Lloyd Referencia : Anticancer Res. 2011 Jun;31(6):2283-90. PMID : 21737653 En línea : http://ar.iiarjournals.org/content/31/6/2283.full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3555 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000124 AC-2011-009 Archivo digital Producción Científica Artículos científicos Disponible
